Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rilpivirine
Rilpivirine/Emtricitabine/Tenofovir · 1 trial · 1 indication
To compare proportion of subjects successfully maintaining a plasma viral load \<200 copies /mL at week 24 in subjects randomized to rilpivirine/emtricitabine/tenofovir vs. in those randomized to initially continue nevirapine-based ART in this pilot study.
| Arm | Type | Description |
|---|---|---|
| Rilpivirine/Emtricitabine/Tenofovir | ACTIVE_COMPARATOR | "Immediate switch": RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization. |
| Nevirapine/Lamivudine/ plus other NNRTI | ACTIVE_COMPARATOR | "Delayed switch": Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks. |
| Name | Type | Description |
|---|---|---|
| Rilpivirine/Emtricitabine/Tenofovir | DRUG | Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday |
Inclusion Criteria: * HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. A second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test or a previous detectable HIV RNA level * HIV RNA ...
Rilpivirine/Emtricitabine/Tenofovir is an investigational small molecule combination therapy being studied for the treatment of HIV. It is in Phase 2 clinical development, with one completed trial that enrolled 150 participants in Rwanda. The drug is not yet approved and remains under clinical investigation.
Rilpivirine/Emtricitabine/Tenofovir is a combination of three antiretroviral agents: rilpivirine, emtricitabine, and tenofovir. These components work by inhibiting HIV reverse transcriptase, an enzyme essential for viral replication. This targeted mechanism is being evaluated in the treatment of HIV infection.
Rilpivirine/Emtricitabine/Tenofovir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate this combination therapy for HIV.
Rilpivirine/Emtricitabine/Tenofovir is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in treating HIV. One Phase 2 trial has been completed.
Rilpivirine/Emtricitabine/Tenofovir has one completed clinical trial registered as NCT02104700, titled "Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir." This Phase 2 study enrolled 150 adults with HIV in Rwanda and was actively controlled, comparing the switch to a nevirapine-based regimen.
Rilpivirine/Emtricitabine/Tenofovir is a combination product that includes rilpivirine as one of its three active components, along with emtricitabine and tenofovir. While rilpivirine is a single antiretroviral agent, the combination product is a distinct fixed-dose formulation being studied for HIV treatment.